The Roles of Tissue Factor in Malignant Gliomas

This study has been completed.
Sponsor:
Collaborator:
Ontario Cancer Research Network
Information provided by:
Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:
NCT00201903
First received: September 13, 2005
Last updated: May 18, 2007
Last verified: May 2007
  Purpose

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma


Condition
Venous Thromboembolism
Brain Tumors

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: The Roles of Tissue Factor in Malignant Gliomas

Resource links provided by NLM:


Further study details as provided by Ontario Clinical Oncology Group (OCOG):

Enrollment: 30
Study Start Date: January 2004
Study Completion Date: October 2006
Detailed Description:

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • participation in PRODIGE
  • adult patients
  • newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
  • undergone craniotomy or stereotactic biopsy > 2 days and < 4 weeks before

Exclusion Criteria:

  • have known hereditary thrombophilia
  • are receiving experimental antiangiogenic therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00201903

Locations
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112-5550
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Manitoba
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Toronto-Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Ontario Cancer Research Network
Investigators
Study Chair: Agnes Lee, MD Hamilton Health Sciences and McMaster University
Principal Investigator: William Geerts, MD Sunnybrook Health Sciences Centre
Principal Investigator: Mark Levine, MD Ontario Clinical Oncology Group (OCOG)
Principal Investigator: James Perry, MD Toronto Sunnybrook Regional Cancer Centre
Principal Investigator: Janusz Rak Hamilton Health Sciences and McMaster University
Principal Investigator: Jeffrey Weitz, MD Hamilton Health Sciences and McMaster University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00201903     History of Changes
Other Study ID Numbers: OCOG-2003-TFsubstudy
Study First Received: September 13, 2005
Last Updated: May 18, 2007
Health Authority: Canada: Health Canada

Keywords provided by Ontario Clinical Oncology Group (OCOG):
venous thromboembolism
brain tumours
glioma
tissue factor
blood coagulation
tumour progression
low molecular weight heparin

Additional relevant MeSH terms:
Brain Neoplasms
Glioma
Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Thrombosis
Heparin, Low-Molecular-Weight
Thromboplastin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents

ClinicalTrials.gov processed this record on August 20, 2014